Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

NCT04143516 · View on ClinicalTrials.gov ↗

Study Summary

This study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive. The results of these biopsies could help determine the next treatment for your cancer, but the biopsies could cause side effects.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST PET/CT Scan
  • DIAGNOSTIC_TEST [18-F]- FDG - PET
  • PROCEDURE Tumor ablation (TA)

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center — New York

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2019-10-25
Est. Completion 2026-10
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

2,280 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04143516

The ClinicalTrials.gov registry entry for NCT04143516 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 2,280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Liver Metastases appearing as the primary indexed condition, and to 3 interventions — of which PET/CT Scan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04143516 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04143516 about?

NCT04143516 is a clinical study titled "Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment". This study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive. The results of these biopsies could help determine the next treatment for your cancer, but the biopsies...

What is the current status of trial NCT04143516?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2019-10-25. Estimated completion is 2026-10.

What conditions does trial NCT04143516 study?

This clinical trial studies the following conditions: Liver Metastases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04143516?

The interventions under investigation include: PET/CT Scan (DIAGNOSTIC_TEST), [18-F]- FDG - PET (DIAGNOSTIC_TEST), Tumor ablation (TA) (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04143516?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 2,280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04143516 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial